ADHD
Conditions
Keywords
ADHD, OROS-MPH, Adults, Functional Magnetic Resonance Imaging
Brief summary
The primary aim of this study is to assess the predictability of treatment response to stimulants in adults with ADHD using functional magnetic resonance This study will be a six-week, open-label study including adults ranging from age 18-55 with ADHD.
Detailed description
Certain brain characteristics have been identified in individuals with persistent and remitted ADHD. We predict that neural functional connectivity; specifically decreases in connectivity between the posterior cingulated cortex and medial prefrontal cortex, as well as decreases in anticorrelations between the medial prefrontal cortex and dorsolateral prefrontal cortex, will predict greater response to stimulant treatment.
Interventions
DRUGOROS-MPH
Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
Sponsors
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Male or female adults ages 18-55 years * Right handed * A diagnosis current of childhood onset ADHD, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) based on clinical assessment * A score of \> 20 on the Adult ADHD Investigator Symptom Report Scale (AISRS) or a CGI-Severity score of \> 4 (moderate severity)
Exclusion criteria
* A history of non-response or intolerance to stimulants at adequate doses as determined by the clinician * Pregnant or nursing females * Serious, unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrinologic (thyroid), neurologic (seizure), immunologic, or hematologic disease * Glaucoma * Clinically unstable psychiatric conditions including suicidality, homocidality, bipolar disorder, psychosis, or lifetime history of a clinically serious condition potentially exacerbated by a stimulant, such as mania or psychosis * Tics or diagnosis of Tourette's syndrome * Current (within 3 months) DSM-IV criteria for abuse or dependence with any psychoactive substance other than nicotine * Current use of psychotropic medications * Current use of MAO Inhibitor or use within the past two weeks * Claustrophobia or an standard contraindications to MRI scanning (metal in body) * Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent or grandchild
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adult Investigator Rating Scale | Baseline to 6 weeks | AISRS |
Countries
United States
Outcome results
None listed